Vosoritide is a 39-amino-acid analog of C-type natriuretic peptide, a natural signal that drives growth at the ends of long bones. It is approved to increase growth in children with achondroplasia. This guide covers its structure, mechanism, labeled use, trials and label warnings. Sources were checked on November 17, 2026.
Quick answer: Vosoritide is a prescription peptide sold as Voxzogo by BioMarin. Its label covers increasing linear growth in children with achondroplasia whose growth plates are still open. It has no boxed warning. The main label warning is a risk of low blood pressure.
Vitrapep does not sell vosoritide; this page is a reference summary of published research and regulatory information.
What is vosoritide?
The Voxzogo label describes vosoritide as “a human C type natriuretic peptide (CNP) analog.” It states plainly: “Vosoritide is a 39 amino acid peptide.” The label gives a formula of C176H290N56O51S3 and a molecular weight of 4.1 kDa (Voxzogo label, 2024). PubChem lists the same formula and a molecular weight of 4,103 g/mol (PubChem CID 119058036).
CNP is a natriuretic peptide, like B-type natriuretic peptide, the basis of the heart-failure drug nesiritide. For the basics of peptide structure, see our peptide primer.
Drugs@FDA lists the original approval of Voxzogo (NDA 214938) on November 19, 2021, to BioMarin (Drugs@FDA). It also lists an efficacy supplement for a new patient population, approved on October 20, 2023.
Vosoritide: key facts
| Fact | Detail |
|---|---|
| Structure type | Analog of human C-type natriuretic peptide, 39 amino acids |
| Class | C-type natriuretic peptide (CNP) analog; NPR-B agonist |
| Molecular formula | C176H290N56O51S3 |
| Molecular weight | 4,103 g/mol (about 4.1 kDa) |
| First FDA approval | November 19, 2021 (Voxzogo, NDA 214938; accelerated approval) |
| Brand names (US) | Voxzogo (BioMarin) |
How does vosoritide work?
The label explains the problem first. “In patients with achondroplasia, endochondral bone growth is negatively regulated due to a gain of function mutation in fibroblast growth factor receptor 3 (FGFR3).” Endochondral growth is the process that lengthens long bones at the growth plates. The overactive FGFR3 signal acts like a brake on it.
Vosoritide works against that brake. “Binding of vosoritide to natriuretic peptide receptor-B (NPR-B) antagonizes FGFR3 downstream signaling.” As a result, it states, vosoritide, “like CNP, acts as a positive regulator of endochondral bone growth” (Voxzogo label, 2024). It does this by promoting the growth and maturation of cartilage cells. In animal models with open growth plates, it widened the growth plate and increased skeletal growth. The label limits use to children whose growth plates, or epiphyses, are still open.
What is vosoritide approved for?
The Voxzogo label states: “VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses.”
The label adds that this indication “is approved under accelerated approval based on an improvement in annualized growth velocity.” It also states that “continued approval for this indication may be contingent upon verification and description of clinical benefit.” In plain terms, the approval rests on yearly growth rate rather than final adult height.
What did the key trials show?
Phase 3, ages 5 to 17. The pivotal human trial was a 52-week, randomized, double-blind, placebo-controlled, multicenter study. It enrolled 121 children with achondroplasia: 60 on vosoritide and 61 on placebo. The primary end point was the change from baseline in annualized growth velocity.
The adjusted mean difference was 1.57 cm per year in favor of vosoritide (95% CI, 1.22 to 1.93; P < 0.0001). Adverse events occurred in 98% of both groups. No serious adverse events were judged to be related to treatment (Savarirayan et al., 2020). The registry record is NCT03197766.
Phase 2, infants and young children. A randomized, double-blind, placebo-controlled trial studied children aged up to 59 months. Of 75 enrolled, 32 were randomized to vosoritide and 32 to placebo. The difference in height Z-score at 52 weeks was 0.25 (95% CI, −0.02 to 0.53), an interval that includes zero. Serious adverse events occurred in 7% of the vosoritide group and 19% of the placebo group (Savarirayan et al., 2024; NCT03583697).
What side effects does the label list?
The Voxzogo label has no boxed warning. Its highlights list the most common adverse reactions, each above 10%. These are site erythema, site swelling, rash, vomiting, site urticaria, arthralgia, decreased blood pressure and gastroenteritis. Here, “site” means where the drug is given. Selected rates, Voxzogo versus placebo, were:
- Site erythema (redness): 75% versus 69%
- Site swelling: 62% versus 36%
- Vomiting: 27% versus 20%
- Site urticaria (hives): 25% versus 10%
- Arthralgia (joint pain): 15% versus 7%
- Decreased blood pressure: 13% versus 5%
The only warning section is titled “Risk of Low Blood Pressure.” The label notes that blood pressure drops were seen in trials. Children with significant heart or vascular disease, or on blood pressure drugs, were excluded from the trials (Voxzogo label, 2024).
What is vosoritide’s regulatory status, and how is it used in research?
Vosoritide is a prescription drug in the United States, approved under the accelerated pathway. On July 13, 2026, BioMarin said FDA had accepted a supplemental application for full approval in children with achondroplasia. The filing draws on long-term data, including adult height, and has a target action date of February 28, 2027 (BioMarin, 2026a).
Vosoritide is not approved for hypochondroplasia. BioMarin reported on May 20, 2026, that its phase 3 CANOPY-HCH-3 trial in 80 children met its primary end point. Growth velocity rose by 2.33 cm per year more than with placebo (P < 0.0001). The company planned a U.S. filing in the third quarter of 2026 (BioMarin, 2026b). These are company-reported, human data. We found no documented role as a laboratory reagent in the sources we checked.
Frequently asked questions about vosoritide
Is vosoritide a peptide?
Yes. The label calls it a 39-amino-acid peptide and an analog of C-type natriuretic peptide.
When was vosoritide approved?
Drugs@FDA lists the original approval of Voxzogo on November 19, 2021.
Does vosoritide increase final adult height?
The approval rests on yearly growth rate, not adult height. BioMarin’s pending full-approval filing includes adult height data, which FDA has not yet ruled on.
Why does it only work in children?
The label limits use to patients with open epiphyses, the growth plates where long bones lengthen. Its mechanism acts on growth-plate cartilage cells.
Does vosoritide have a boxed warning?
No. Its one warning section covers the risk of low blood pressure.
What to know now
- Structure: 39-amino-acid CNP analog; C176H290N56O51S3; about 4.1 kDa.
- Approval: Voxzogo, November 19, 2021, under accelerated approval.
- Mechanism: binds NPR-B and counters FGFR3 signaling in the growth plate.
- Evidence: 1.57 cm per year faster growth than placebo in the phase 3 trial.
- Safety: no boxed warning; site reactions, vomiting and low blood pressure are common.
- Next: full-approval decision target, February 28, 2027.
What we’re watching
FDA’s action on the full-approval application by February 28, 2027. Whether BioMarin’s planned hypochondroplasia filing is accepted. Related guides: nesiritide, teriparatide and types of peptides.